SVB Securities analyst Andrew Berens maintained a Hold rating on Blueprint Medicines (BPMC – Research Report) today and set a price target of $65.00. The company's shares closed last Tuesday at $56.29. According to TipRanks.com, Berens has 0 stars on 0-5 stars ranking scale with an average return of -5.0% and a 45.4% success rate. Berens covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Turning Point Therapeutics, and Global Blood Therapeutics. Blueprint Medicines has an analyst consensus of Moderate Buy, with a price target consensus of $81.75, representing a 63.5% upside.
https://www.tipranks.com/news/blurbs/blueprint-medicines-bpmc-gets-a-hold-rating-from-svb-securities-2?utm_source=advfn.com&utm_medium=referral
Blueprint Medicines (NASDAQ:BPMC)
Historical Stock Chart
From Aug 2022 to Sep 2022 Click Here for more Blueprint Medicines Charts.
Blueprint Medicines (NASDAQ:BPMC)
Historical Stock Chart
From Sep 2021 to Sep 2022 Click Here for more Blueprint Medicines Charts.